Cannabis and Cannabinoids (PDQ®)–Health Professional Version
Changes to This Summary (01/17/2019)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that intercellular adhesion molecule-1 expression in tumor cells has been reported to be negatively correlated with cancer metastasis.
Added text to state that highly concentrated delta-9-tetrahydrocannabinol or cannabidiol (CBD) oil extracts are being illegally promoted as potential cancer cures (cited Food and Drug Administration News Release as reference 5). These oils have not been evaluated in any clinical trials for anticancer activity or safety. Because CBD is a potential inhibitor of certain cytochrome p450 enzymes, highly concentrated CBD oils used concurrently with conventional therapies that are metabolized by these enzymes could potentially increase toxicity or decrease the effectiveness of these therapies (cited Yamaori et al. and Jiang et al. as references 6 and 7, respectively).
Added text to state that CBD is an inhibitor of cytochrome p450 isoforms in vitro. Because many anticancer therapies are metabolized by these enzymes, highly concentrated CBD oils used concurrently could potentially increase the toxicity or decrease the effectiveness of these therapies (cited Yamaori et al. and Jiang et al. as references 5 reference 6, respectively).
This summary is written and maintained by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
.png)
No hay comentarios:
Publicar un comentario